Carmine Therapeutics
PrivateLast Round
Series A
Oct 13, 2022
Total Funding Raised
$22.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Carmine Therapeutics is a biotechnology company that develops non-viral gene therapies using its proprietary red blood cell extracellular vesicle (RBCEV) platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Carmine Therapeutics Comparables
Compare Carmine Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| STRM.BIO | 88% | |
| Anjarium Biosciences | 87% | |
| Vesigen Therapeutics | 87% |
Carmine Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 13, 2022 | ||||
| Convertible Debt | Jun 30, 2020 | ||||
| Seed | Aug 28, 2019 |
Key People
Founding team and executive leadership
Carmine Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cystic Fibrosis Foundation | Series A |
| Huagai Capital | Series A |
| EVX Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 119% MoM, reaching 4.2K.
- Jun 20, 2026
Monthly visitors grew 98% MoM.
Carmine Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Carmine Therapeutics's valuation, stock price, and market status.
Is Carmine Therapeutics a public or private company?
Carmine Therapeutics is a private company.
What is the current stock price of Carmine Therapeutics?
Carmine Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Carmine Therapeutics worth (valuation)?
Valuation information for Carmine Therapeutics is not publicly available.
Can I buy Carmine Therapeutics stock?
Carmine Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Carmine Therapeutics's last funding round?
Carmine Therapeutics's most recent funding round was Series A on October 13, 2022.
Who are the main investors in Carmine Therapeutics?
Key investors in Carmine Therapeutics include Huagai Capital, EVX Ventures.
Will Carmine Therapeutics IPO soon?
No public IPO plans have been announced for Carmine Therapeutics.
How can I track Carmine Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Carmine Therapeutics's secondary market activity and sign up for updates.